BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Quick Stats
59.4
AI Score
HOLD0.06
Volume Ratio
Next Earnings
15
+ve Days (30d)
14
-ve Days (30d)
BBIO Stock Summary
Last updated Jan 27, 2026
BBIO is currently trading at $78.16, positioned below its 200-day moving average of $, suggesting bearish momentum. The stock has a 52-week range of $28.325 to $81.325.
Technical Analysis: The 50-day moving average stands at $, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 56.276, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.136, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates BBIO at 59.4/100 with a HOLD recommendation.
BBIO (BridgeBio Pharma, Inc. Common Stock) Indicators
Last updated Jan 27, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 56.276 |
| CMF (20) | 0.136 |
| ROC (10) | 1.34 |
| ADX (14) | 15.843 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | 1.317 |
| AROONOSC (14) | 50.0 |
| WILLAMS %R (14) | -33.301 |
| MFI (14) | 48.368 |
BBIO Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
BBIO Price vs Max Options Open Interest
BBIO Max Change In Options Open Interest
BBIO Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
BBIO Daily Out of Money Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
BBIO Daily In the Money Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
BBIO Most Active Options by Volume(near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
BridgeBio Pharma, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
BBIO Moving Averages Analysis
BBIO (BridgeBio Pharma, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated
| Days | MA |
|---|
BBIO Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 14.8 billion |
| Earnings/Share ($) | -4.11 |
| Net Proft Margin (%) | -2.2532 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -3.19 |
| EPS Estimate Next Year ($) | -1.7733 |
| WallStreet Target Price ($) | 93.15 |
| Most Recent Quarter |